A Science & Innovation Webinar, presented by Abbvie.

The intent of evidence-based health care decision making is to compare all applicable and available treatment options. When direct comparisons from randomized controlled trials are not available, indirect treatment comparisons, including network meta-analyses, may offer valuable insights. In addition, mixed treatment comparisons, a type of network meta-analysis, combine both direct and indirect evidence for specific comparisons, providing a broader view than traditional network meta analysis.

A Science & Innovation Webinar, presented by Abbvie.

Migraine is a complex, chronic disease that results in significant patient and economic burden. It is important to appropriately manage a person with migraine who experiences greater than 4 attacks a month (or severe disability from at least two attacks a month) and may benefit from preventive therapy. One of the main goals of preventive therapy is to improve function and reduce disability. Utilizing a stratified care approach to preventive migraine treatment is key to accomplish this goal. During this webinar, a migraine expert will discuss the complexity of migraine disease and the burden of the disease as it relates to function, and the treatment landscape, with a focus on a preventive treatment option for adults with migraine.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Soleno Therapeutics.

Soleno Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of a novel therapy to treat Hyperphagia in Prader-Willi syndrome (PWS), a rare and life-threatening neurobehavioral, metabolic and endocrine disorder characterized by hyperphagia, neurocognitive and behavioral difficulties. The company is currently pursuing regulatory approval in the United States for its lead investigational candidate, DCCR (diazoxide choline) extended-release tablets.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Alnylam Pharmaceuticals, Inc.

Transthyretin amyloidosis (ATTR) is an underdiagnosed, progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the heart, nerves, and gastrointestinal tract. Please join Alnylam Pharmaceuticals as we review the disease state, clinical symptoms and epidemiology for the Cardiomyopathy manifestation of the disease followed by a review of the study results for the Phase 3 HELIOS-B trial.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Ferring Pharmaceuticals, Inc.

SI-6603 is an investigational product being evaluated for the treatment of radicular leg pain associated with lumbar disc herniation. This pre-approval information exchange (PIE) presentation includes disease overview, an overview of SI-6603 including MOA and pivotal study data along with anticipated timing and access details.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation state and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by Abbvie. 

One of the main goals of acute treatment of migraine is freedom from pain and associated symptoms without recurrence. It is therefore important that every person with migraine, regardless of migraine frequency, be offered a migraine specific treatment that has freedom from pain data, freedom from associated symptom data and evidence that the treatment can prevent a moderate to severe migraine attack. The objective for this webinar is to review the migraine disease state and phases of a migraine attack, and outline clinical data as a treatment option for the acute treatment of migraine.

A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. 

Join a comprehensive webinar that will enhance your decision-making for people living with schizophrenia. This webinar will delve into a disease overview of schizophrenia, shedding light on the often overlooked cognitive symptom domain and its significant clinical and economic burden. The webinar will also uncover the latest understanding of the biological mechanisms and explore a potential new treatment approach to specifically target cognitive symptoms associated with schizophrenia. 

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®. This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.